Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Primary outcome measures:
The time to the first occurrence of any of the elements of the composite of cardiovascular death, myocardial infarction, ischemic stroke, and ischemia-driven coronary revascularisation
Nidorf et al. 2020 N Engl J Med 383: 1838-1847 published the results of 0.5 mg of colchicine once daily or matching placebo to patients with with chronic coronary disease from a randomised, placebo-controlled phase III trial with 5522 subjects.
The authors' conclusion was: In a randomized trial involving patients with chronic coronary disease, the risk of cardiovascular events was significantly lower among those who received 0.5 mg of colchicine once daily than among those who received placebo
…